← back to search

Ramūnas Janavičius

University of California, Los Angeles · US
Area of research
Genetics · Molecular Biology
Research interest
Research interests include BRCA gene mutations in cancer, DNA Repair Mechanisms, Ovarian cancer diagnosis and treatment, and CRISPR and Genetic Engineering.
h-index
34
citations
5,386
works
98
NIH funding
primary concept
Medicine
email

Recent publications

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
2025cited by 0position: contributordoi
Genetic counselling legislation and practice in cancer in EU Member States.
2024cited by 5position: contributordoi
Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk
medRxiv 2024cited by 3position: middledoi
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer 2023cited by 17position: middledoi
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer 2023cited by 17position: contributordoi
A Novel Mutation of <i>MSH2</i> Gene in a Patient with Lynch Syndrome Presenting with Thirteen Metachronous Malignancies.
2023cited by 0position: contributordoi
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants
Journal of Clinical Oncology 2022cited by 258position: contributordoi
Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
2022cited by 53position: contributordoi
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
2022cited by 30position: contributordoi
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications Biology 2022cited by 14position: middledoi
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications Biology 2022cited by 14position: contributordoi
Is rare cancer care organized at national health system level? Multiple case study in six EU countries.
2022cited by 3position: contributordoi
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
2022cited by 2position: contributordoi
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Annals of Oncology 2021cited by 163position: middledoi
Breast and Prostate Cancer Risks for Male<i>BRCA1</i>and<i>BRCA2</i>Pathogenic Variant Carriers Using Polygenic Risk Scores
JNCI Journal of the National Cancer Institute 2021cited by 41position: middledoi
Breast and Prostate Cancer Risks for Male<i>BRCA1</i>and<i>BRCA2</i>Pathogenic Variant Carriers Using Polygenic Risk Scores
JNCI: Journal of the National Cancer Institute 2021cited by 37position: contributordoi
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants
Genetics in Medicine 2021cited by 29position: middledoi
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
2021cited by 22position: contributordoi
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.
2020cited by 413position: contributordoi
Cancer Risks Associated With Germline &lt;i&gt;PALB2&lt;/i&gt; Pathogenic Variants: An International Study of 524 Families.
2020cited by 315position: contributordoi
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i>
JNCI Journal of the National Cancer Institute 2020cited by 161position: middledoi
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics 2020cited by 161position: contributordoi
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i>
JNCI: Journal of the National Cancer Institute 2020cited by 140position: contributordoi
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
2020cited by 99position: contributordoi
Characterization of the Cancer Spectrum in Men With Germline<i>BRCA1</i>and<i>BRCA2</i>Pathogenic Variants
JAMA Oncology 2020cited by 66position: middledoi
Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness
Cancer Research 2020cited by 48position: contributordoi
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.
2020cited by 35position: contributordoi
The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases
Cancers 2020cited by 11position: contributordoi
The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
2020cited by 10position: contributordoi
Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families
Journal of Clinical Oncology 2019cited by 409position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hans Ehrencrona · Institute of Haematology and Blood Transfusion3 papers (2020–2025)Christoph Engel · University of Regensburg3 papers (2020–2025)Paolo Peterlongo · Institut d'Investigació Biomèdica de Girona2 papers (2020–2022)Irene Konstantopoulou · Carmel Medical Center2 papers (2020–2025)Siranoush Manoukian · University College London2 papers (2020–2022)Esther M. John · Westmead Institute for Medical Research2 papers (2022–2025)Anna Benet‐Pagès · LMU Klinikum1 papers (2016–2016)Geertruida H. de Bock · University Medical Center Groningen1 papers (2025–2025)Andreas Rump · Carl von Ossietzky Universität Oldenburg1 papers (2016–2016)Steffen Emmert · UConn Health1 papers (2016–2016)Jan Dominik Kuhlmann · German Cancer Research Center1 papers (2016–2016)Eva Macháčková · Monash University1 papers (2016–2016)Anke M. Nissen · LMU Klinikum1 papers (2016–2016)D. Gareth Evans · Translational Research Institute1 papers (2025–2025)Patricia A. Ganz · University College London1 papers (2025–2025)Dragan Primorac · Public Risk Management Association1 papers (2024–2024)Tim Ripperger · Cancer Research Institute Ghent1 papers (2024–2024)Jeffrey N. Weitzel · University of Rostock1 papers (2020–2020)Fabienne Lesueur · Leeds Teaching Hospitals NHS Trust1 papers (2020–2020)Laura Ottini · Monash University1 papers (2020–2020)